Log in

NASDAQ:POAI - Precision Therapeutics Stock Price, Forecast & News

+0.01 (+0.33 %)
(As of 12/8/2019 02:27 AM ET)
Today's Range
Now: $3.01
50-Day Range
MA: $2.94
52-Week Range
Now: $3.01
Volume48,013 shs
Average Volume12,385 shs
Market Capitalization$11.70 million
P/E RatioN/A
Dividend YieldN/A
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Current SymbolNASDAQ:POAI



Sales & Book Value

Annual Sales$1.41 million
Book Value$0.04 per share


Net Income$-10,090,000.00
Net Margins-674.64%


Market Cap$11.70 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive POAI News and Ratings via Email

Sign-up to receive the latest news and ratings for POAI and its competitors with MarketBeat's FREE daily newsletter.

Precision Therapeutics (NASDAQ:POAI) Frequently Asked Questions

What is Precision Therapeutics' stock symbol?

Precision Therapeutics trades on the NASDAQ under the ticker symbol "POAI."

How were Precision Therapeutics' earnings last quarter?

Precision Therapeutics Inc (NASDAQ:POAI) posted its quarterly earnings results on Tuesday, August, 14th. The medical instruments supplier reported ($0.20) earnings per share (EPS) for the quarter. The medical instruments supplier earned $0.36 million during the quarter. Precision Therapeutics had a negative return on equity of 86.24% and a negative net margin of 674.64%. View Precision Therapeutics' Earnings History.

When is Precision Therapeutics' next earnings date?

Precision Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Precision Therapeutics.

Has Precision Therapeutics been receiving favorable news coverage?

News stories about POAI stock have been trending extremely negative on Sunday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Precision Therapeutics earned a news impact score of -4.6 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Precision Therapeutics.

Are investors shorting Precision Therapeutics?

Precision Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totalling 45,200 shares, a drop of 88.7% from the October 31st total of 400,000 shares. Based on an average trading volume of 13,600 shares, the short-interest ratio is currently 3.3 days. Currently, 1.9% of the company's stock are sold short. View Precision Therapeutics' Current Options Chain.

Who are some of Precision Therapeutics' key competitors?

What other stocks do shareholders of Precision Therapeutics own?

Who are Precision Therapeutics' key executives?

Precision Therapeutics' management team includes the folowing people:
  • Dr. Carl I. Schwartz, CEO & Director (Age 78)
  • Mr. Robert L. Myers, CFO & Sec. (Age 64)
  • Mr. David Orrin Johnson, Sr. VP of Operations - Skyline Medical Bus. Unit (Age 66)
  • Mr. Kevin Hungerford, VP of Sales & Marketing

How do I buy shares of Precision Therapeutics?

Shares of POAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Precision Therapeutics' stock price today?

One share of POAI stock can currently be purchased for approximately $3.01.

How big of a company is Precision Therapeutics?

Precision Therapeutics has a market capitalization of $11.70 million and generates $1.41 million in revenue each year. Precision Therapeutics employs 24 workers across the globe.View Additional Information About Precision Therapeutics.

What is Precision Therapeutics' official website?

The official website for Precision Therapeutics is http://www.precisiontherapeutics.com/.

How can I contact Precision Therapeutics?

Precision Therapeutics' mailing address is 2915 COMMERS DRIVE SUITE 900, EAGAN MN, 55121. The medical instruments supplier can be reached via phone at 651-389-4800 or via email at [email protected]

MarketBeat Community Rating for Precision Therapeutics (NASDAQ POAI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  130 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Precision Therapeutics and other stocks. Vote "Outperform" if you believe POAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel